Skip to main content

ESTUDIO DE LOS EFECTOS DE LA VITAMINA D EN LA FISIOLOGIA Y PATOLOGIA DEL COLON HUMANO USANDO ORGANOIDES Y CULTIVOS PRIMARIOS DE FIBROBLASTOS DERIVADOS DE PACIENTES

PID2019-104867RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 23
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Vitamin D opposes multilineage cell differentiation induced by Notch inhibition and BMP4 pathway activation in human colon organoids

  • Bustamante Madrid, Pilar
  • Barbáchano, Antonio
  • Albandea Rodríguez, David
  • Rodríguez Cobos, Javier
  • Rodríguez Salas, Nuria
  • Prieto Nieto, Isabel
  • Burgos García, Aurora
  • Martínez de Villarreal, Jaime
  • Real, Francisco X.
  • González Sancho, José Manuel
  • Larriba, María Jesús
  • Lafarga, Miguel
  • Muñoz, Alberto
  • Fernández Barral, Asunción
Understanding the mechanisms involved in colonic epithelial differentiation is key to unraveling the alterations causing inflammatory conditions and cancer. Organoid cultures provide an unique tool to address these questions but studies are scarce. We report a differentiation system toward enterocytes and goblet cells, the two major colonic epithelial cell lineages, using colon organoids generated from healthy tissue of colorectal cancer patients. Culture of these organoids in medium lacking stemness agents resulted in a modest ultrastructural differentiation phenotype with low-level expression of enterocyte (KLF4, KRT20, CA1, FABP2) and goblet cell (TFF2, TFF3, AGR2) lineage markers. BMP pathway activation through depletion of Noggin and addition of BMP4 resulted in enterocyte-biased differentiation. Contrarily, blockade of the Notch pathway using the γ-secretase inhibitor dibenzazepine (DBZ) favored goblet cell differentiation. Combination treatment with BMP4 and DBZ caused a balanced strong induction of both lineages. In contrast, colon tumor organoids responded poorly to BMP4 showing only weak signals of cell differentiation, and were unresponsive to DBZ. We also investigated the effects of 1α,25-dihydroxyvitamin D3 (calcitriol) on differentiation. Calcitriol attenuated the effects of BMP4 and DBZ on colon normal organoids, with reduced expression of differentiation genes and phenotype. Consistently, in normal organoids, calcitriol inhibited early signaling by BMP4 as assessed by reduction of the level of phospho-SMAD1/5/8. Our results show that BMP and Notch signaling play key roles in human colon stem cell differentiation to the enterocytic and goblet cell lineages and that calcitriol modulates these processes favoring stemness features., This work was supported by grant PID2019-104867RB-I00 funded by MCIN/AEI/10.13039/501100011033; grant PID2022-136729OB-I00 funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe”; grant S2022/BMD-7212 funded by Comunidad de Madrid; and grants ICI20/00057, CIBERONC/CB16/12/00273, CIBERONC/CB16/12/00453 and CIBERONC/CB16/12/00398 funded by the Instituto de Salud Carlos III - Fondo Europeo de Desarrollo Regional. PB-M and DA-R were supported by grants BES-2017-082483 and PRE2020-092713, respectively, funded by MCIN/AEI/10.13039/501100011033 and “ESF Investing in your future”. PB-M, AB, DA-R, JR-C, JMG-S, MJL, AM and AF-B belong to the Spanish National Research Council (CSIC)‘s Cancer Hub.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Comparative study of organoids from patient-derived normal and tumor colon and rectal tissue

  • Costales-Carrera, Alba
  • Fernández-Barral, Asunción
  • Bustamante-Madrid, Pilar
  • Domínguez, Orlando
  • Guerra-Pastrián, Laura
  • Cantero, Ramón
  • Peso, Luis del
  • Burgos, Aurora
  • Barbáchano, Antonio
  • Muñoz Terol, Alberto
This article belongs to the Special Issue Stemness and Differentiation in Cancer., Colon and rectal tumors, often referred to as colorectal cancer, show different gene expression patterns in studies that analyze whole tissue biopsies containing a mix of tumor and non-tumor cells. To better characterize colon and rectal tumors, we investigated the gene expression profile of organoids generated from endoscopic biopsies of rectal tumors and adjacent normal colon and rectum mucosa from therapy-naive rectal cancer patients. We also studied the effect of vitamin D on these organoid types. Gene profiling was performed by RNA-sequencing. Organoids from a normal colon and rectum had a shared gene expression profile that profoundly differed from that of rectal tumor organoids. We identified a group of genes of the biosynthetic machinery as rectal tumor organoid-specific, including those encoding the RNA polymerase II subunits POLR2H and POLR2J. The active vitamin D metabolite 1α,25-dihydroxyvitamin D3/calcitriol upregulated stemness-related genes (LGR5, LRIG1, SMOC2, and MSI1) in normal rectum organoids, while it downregulated differentiation marker genes (TFF2 and MUC2). Normal colon and rectum organoids share similar gene expression patterns and respond similarly to calcitriol. Rectal tumor organoids display distinct and heterogeneous gene expression profiles, with differences with respect to those of colon tumor organoids, and respond differently to calcitriol than normal rectum organoids., This research was founded by Agencia Estatal de Investigación (PID2019-104867RB-I00/AEI/10.13039/501100011033), Agencia Estatal de Investigación-Fondo Europeo de Desarrollo Regional (SAF2016-76377-R, MINECO/AEI/FEDER, UE), Ministerio de Economía y Competitividad (SAF2017-90604-REDT), Instituto de Salud Carlos III—Fondo Europeo de Desarrollo Regional (CIBERONC, CB16/12/00273; CIBERES, CB15/00037), and Mutua Madrileña., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Vitamin D effects on cell differentiation and stemness in cancer

  • Fernández-Barral, Asunción
  • Bustamante-Madrid, Pilar
  • Ferrer-Mayorga, Gemma
  • Barbáchano, Antonio
  • Larriba, María Jesús
  • Muñoz Terol, Alberto
This article belongs to the Special Issue Stemness and Differentiation in Cancer., Vitamin D3 is the precursor of 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), a pleiotropic hormone that is a major regulator of the human genome. 1,25(OH)2D3 modulates the phenotype and physiology of many cell types by controlling the expression of hundreds of genes in a tissue- and cell-specific fashion. Vitamin D deficiency is common among cancer patients and numerous studies have reported that 1,25(OH)2D3 promotes the differentiation of a wide panel of cultured carcinoma cells, frequently associated with a reduction in cell proliferation and survival. A major mechanism of this action is inhibition of the epithelial–mesenchymal transition, which in turn is largely based on antagonism of the Wnt/β-catenin, TGF-β and EGF signaling pathways. In addition, 1,25(OH)2D3 controls the gene expression profile and phenotype of cancer-associated fibroblasts (CAFs), which are important players in the tumorigenic process. Moreover, recent data suggest a regulatory role of 1,25(OH)2D3 in the biology of normal and cancer stem cells (CSCs). Here, we revise the current knowledge of the molecular and genetic basis of the regulation by 1,25(OH)2D3 of the differentiation and stemness of human carcinoma cells, CAFs and CSCs. These effects support a homeostatic non-cytotoxic anticancer action of 1,25(OH)2D3 based on reprogramming of the phenotype of several cell types., The work in the authors’ laboratory is funded by the Agencia Estatal de Investigación (PID2019-104867RB-I00/AEI/10.13039/501100011033), the Agencia Estatal de Investigación-Fondo Europeo de Desarrollo Regional (SAF2016-76377-R, MINECO/AEI/FEDER, EU), the Ministerio de Economía y Competitividad (SAF2017-90604-REDT/NuRCaMeIn), and the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (CIBERONC; CB16/12/00273)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Wnt and vitamin D at the crossroads in solid cancer

  • González-Sancho, José Manuel
  • Larriba, María Jesús
  • Muñoz Terol, Alberto
This article belongs to the Special Issue Targeting Wnt Signaling in Cancer: Opportunities Abound If We Can Avoid the Sword of Damocles., [Simple Summary]: The Wnt/β-catenin signaling pathway is aberrantly activated in most colorectal cancers and less frequently in a variety of other solid neoplasias. Many epidemiological and experimental studies and some clinical trials suggest an anticancer action of vitamin D, mainly against colorectal cancer. The aim of this review was to analyze the literature supporting the interference of Wnt/β-catenin signaling by the active vitamin D metabolite 1α,25-dihydroxyvitamin D3. We discuss the molecular mechanisms of this antagonism in colorectal cancer and other cancer types. Additionally, we summarize the available data indicating a reciprocal inhibition of vitamin D action by the activated Wnt/β-catenin pathway. Thus, a complex mutual antagonism between Wnt/β-catenin signaling and the vitamin D system seems to be at the root of many solid cancers., Abnormal activation of the Wnt/β-catenin pathway is common in many types of solid cancers. Likewise, a large proportion of cancer patients have vitamin D deficiency. In line with these observations, Wnt/β-catenin signaling and 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active vitamin D metabolite, usually have opposite effects on cancer cell proliferation and phenotype. In recent years, an increasing number of studies performed in a variety of cancer types have revealed a complex crosstalk between Wnt/β-catenin signaling and 1,25(OH)2D3. Here we review the mechanisms by which 1,25(OH)2D3 inhibits Wnt/β-catenin signaling and, conversely, how the activated Wnt/β-catenin pathway may abrogate vitamin D action. The available data suggest that interaction between Wnt/β-catenin signaling and the vitamin D system is at the crossroads in solid cancers and may have therapeutic applications., The work in the authors’ laboratory is funded by the Agencia Estatal de Investigación (PID2019-104867RB-I00/AEI/10.13039/501100011033), the Agencia Estatal de Investigación—Fondo Europeo de Desarrollo Regional (SAF2016-76377-R, MINECO/AEI/FEDER, EU), the Ministerio de Economía y Competitividad (SAF2017-90604-REDT/NuRCaMeIn), and the Instituto de Salud Carlos III—Fondo Europeo de Desarrollo Regional (CIBERONC; CB16/12/00273)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Organoids and colorectal cancer

  • Barbáchano, Antonio
  • Fernández-Barral, Asunción
  • Bustamante-Madrid, Pilar
  • Prieto, Isabel
  • Rodríguez-Salas, Nuria
  • Larriba, María Jesús
  • Muñoz Terol, Alberto
This article belongs to the Special Issue Three-Dimensional Culture Systems in Cancer Research., [Simple Summary]: Colorectal cancer is one of the most frequent and lethal types of cancer. Despite advances in recent decades, our knowledge of this disease is still limited, and novel and better therapies are needed. Organoids were recently developed as a new system to culture normal and tumor cells obtained from patients subjected to surgery or endoscopic tests. Organoids are being used to dissect the molecular and genetic bases of colorectal cancer initiation and progression. In this review, we describe how patient-derived organoids can be generated, and their use to investigate in depth the tumorigenic process. We show how this system has allowed the study of colorectal tumorigenesis features for the first time, including immunotherapy, interplay with microorganisms and, more importantly, assays of drug treatments at an individualized level. Additionally, we summarize the most recent developments of what is known as organoid technology directed towards personalized medicine., [Abstract]: Organoids were first established as a three-dimensional cell culture system from mouse small intestine. Subsequent development has made organoids a key system to study many human physiological and pathological processes that affect a variety of tissues and organs. In particular, organoids are becoming very useful tools to dissect colorectal cancer (CRC) by allowing the circumvention of classical problems and limitations, such as the impossibility of long-term culture of normal intestinal epithelial cells and the lack of good animal models for CRC. In this review, we describe the features and current knowledge of intestinal organoids and how they are largely contributing to our better understanding of intestinal cell biology and CRC genetics. Moreover, recent data show that organoids are appropriate systems for antitumoral drug testing and for the personalized treatment of CRC patients., The work in the authors’ laboratory is funded by the Agencia Estatal de Investigación (PID2019-104867RB-I00/AEI/10.13039/501100011033), the Ministerio de Ciencia e Innovación (SAF2017-90604-REDT/NuRCaMeIn), and the Instituto de Salud Carlos III—Fondo Europeo de Desarrollo Regional (CIBERONC/CB16/12/00273, CIBERONC/CB16/12/00398 and ICI20/00057)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Vitamin D and Cancer: An historical overview of the epidemiology and mechanisms

  • Muñoz Terol, Alberto
  • Grant, William B.
This article belongs to the Special Issue A Commemorative Issue in Honor of Centennial of the Discovery of Vitamin D-The Central Role of Vitamin D in Physiology., This is a narrative review of the evidence supporting vitamin D’s anticancer actions. The first section reviews the findings from ecological studies of cancer with respect to indices of solar radiation, which found a reduced risk of incidence and mortality for approximately 23 types of cancer. Meta-analyses of observational studies reported the inverse correlations of serum 25-hydroxyvitamin D [25(OH)D] with the incidence of 12 types of cancer. Case-control studies with a 25(OH)D concentration measured near the time of cancer diagnosis are stronger than nested case-control and cohort studies as long follow-up times reduce the correlations due to changes in 25(OH)D with time. There is no evidence that undiagnosed cancer reduces 25(OH)D concentrations unless the cancer is at a very advanced stage. Meta-analyses of cancer incidence with respect to dietary intake have had limited success due to the low amount of vitamin D in most diets. An analysis of 25(OH)D-cancer incidence rates suggests that achieving 80 ng/mL vs. 10 ng/mL would reduce cancer incidence rates by 70 ± 10%. Clinical trials have provided limited support for the UVB-vitamin D-cancer hypothesis due to poor design and execution. In recent decades, many experimental studies in cultured cells and animal models have described a wide range of anticancer effects of vitamin D compounds. This paper will review studies showing the inhibition of tumor cell proliferation, dedifferentiation, and invasion together with the sensitization to proapoptotic agents. Moreover, 1,25-(OH)2D3 and other vitamin D receptor agonists modulate the biology of several types of stromal cells such as fibroblasts, endothelial and immune cells in a way that interferes the apparition of metastases. In sum, the available mechanistic data support the global protective action of vitamin D against several important types of cancer., The work in A.M. laboratory is funded by the Agencia Estatal de Investigación (PID2019-104867RB-I00/AEI/10.13039/501100011033) and the Instituto de Salud Carlos III—Fondo Europeo de Desarrollo Regional (CIBERONC/CB16/12/00273)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

p38γ and p38δ as biomarkers in the interplay of colon cancer and inflammatory bowel diseases

  • Fajardo, Pilar
  • Taskova, Maria
  • Martín-Serrano, Miguel A.
  • Hansen, Jonas
  • Slott, Sofie
  • Jakobsen, Anna K.
  • Wibom, Marie-Louise
  • Salegi, Beñat
  • Muñoz Terol, Alberto
  • Barbáchano, Antonio
  • Sharma, Arpita
  • Gubatan, John Mark
  • Habtezion, Aida
  • Sanz-Ezquerro, Juan José
  • Astakhova, Kira
  • Cuenda, Ana
descripción no proporcionada por scopus, This research was funded by the MCIN/AEI/10.13039/501100011033 (PID2019-108349RB100 and SAF2016-79792R) to AC and JJSE; Villum Foundation, grant no. 13152 to KA; by Agencia Estatal de Investigación (PID2019-104867RBI00/AEI/10.13039/501100011033) and the Instituto de Salud Carlos III- Fondo Europeo de Desarrollo Regional (CIBERONC/CB16/12/00273 and ICI20/00057) to AM and AB. PF received MCIN FPI fellowship (BES-2017-080139).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis

  • Solé, Laura
  • Lobo-Jarne, Teresa
  • Álvarez-Villanueva, Daniel
  • Alonso-Marañón, Josune
  • Guillén, Yolanda
  • Guix, Marta
  • Sangrador, Irene
  • Rozalén, Catalina
  • Vert, Anna
  • Barbáchano, Antonio
  • Lop, Joan
  • Salido, Marta
  • Bellosillo, Beatriz
  • García-Romero, Raquel
  • Garrido, Marta
  • González, Jessica
  • Martínez-Iniesta, María
  • López-Arribillaga, Erika
  • Salazar, Ramón
  • Montagut, Clara
  • Torres, Ferrán
  • Iglesias, Mar
  • Celià-Terrassa, Toni
  • Muñoz Terol, Alberto
  • Villanueva, Alberto
  • Bigas, Anna
  • Espinosa, Lluís
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. Using CRC patient-derived organoids (PDO)s, we show that sublethal doses of chemotherapy (CT) does not select previously resistant tumor populations but induces a quiescent state specifically to TP53 wildtype (WT) cancer cells, which is linked to the acquisition of a YAP1-dependent fetal phenotype. Cells displaying this phenotype exhibit high tumor-initiating and metastatic activity. Nuclear YAP1 and fetal traits are present in a proportion of tumors at diagnosis and predict poor prognosis in patients carrying TP53 WT CRC tumors. We provide data indicating the higher efficacy of CT together with YAP1 inhibitors for eradication of therapy resistant TP53 WT cancer cells. Together these results identify fetal conversion as a useful biomarker for patient prognosis and therapy prescription., This work was funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI16/00437 and PI19/00013), Generalitat de Catalunya 2017SGR135, PID2019-104867RB-I00/AEI/10.13039/501100011033 funded by the Agencia Estatal de Investigación and the “Xarxa de Bancs de tumors sponsored by Pla Director d’Oncologia de Catalunya (XBTC), Fundación HNA to A.V. research team in the development of orthoxenografts/PDOX., Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (CIBERONC; CB16/12/00244, CB16/12/00241 and CB16/12/00273). IdiPAZ Biobank is supported by Instituto de Salud Carlos III, Spanish Health Ministry (Grant RD09/0076/00073), and Farmaindustria through the Cooperation Program in Clinical and Translational Research of the Community of Madrid. LS is supported by AGAUR (2018 FI_B 00088/2020 FI_B2 00150). D.A-V was funded by FI20/00130 and Y.G. and T.L-J by a contract from CIBERONC (ISCIII-Feder) and Asociación Española Contra el Cancer (AECC). T.C-T was funded by the Instituto de Salud Carlos III-FSE (MS17/ 00037; PI18/00014). A.V was supported by grant PI19/01320 funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Tailored chemotherapy for colorectal cancer peritoneal metastases based on a drug-screening platform in patient-derived organoids: a case report

  • Prieto, Isabel
  • Barbáchano, Antonio
  • Rodríguez-Salas, Nuria
  • Viñal, David
  • Cortés-Guiral, Delia
  • Muñoz Terol, Alberto
  • Fernández-Barral, Asunción
[Background]: Peritoneal metastasis from colorectal cancer (CRC) has limited therapeutic options and poor prognosis. Systemic chemotherapy combined with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) or pressurized intraperitoneal aerosol chemotherapy (PIPAC) have yielded initial promising results. However, standard local therapies with oxaliplatin and mitomycin are not optimal and a better individualized management of these patients remains as an unmet clinical need. Patient-derived organoid (PDO) technology allows to culture in three dimensions normal and cancer stem cells (CSC) that self-organize in multicellular structures that recapitulates some of the features of the particular organ or tumor of origin, emerging as a promising tool for drug-testing and precision medicine. This technology could improve the efficacy of systemic and intraperitoneal chemotherapy and avoid unnecessary treatments and side effects to the patient., [Case description]: Here we report a case of a 45-year-old man with a rectal adenocarcinoma with liver, lymph node and peritoneal metastases. The patient was treated with systemic chemotherapy (FOLFOXIRI plus Bevacizumab) and was subjected to mitomycin-based PIPAC. We generated patient-derived peritoneal carcinomatosis organoids in order to screen the activity of drugs for a personalized treatment. Both 5-FU and SN-38, the active irinotecan derivative, displayed strong cytotoxicity, while the response to oxaliplatin was much lower. Although the development of a colo-cutaneous fistulae prevented from further PIPAC, the patient continued with fluoropirimidine maintenance treatment based on standard clinical practice and the drug-screening test performed on organoids., [Conclusions]: Our results suggest that the peritoneal implant shows chemoresistance to oxaliplatin, while it might still be sensitive to irinotecan and 5-FU, which supports a potential benefit of these two drugs in the local and/or systemic treatment of our patient. This study shows the strength of the utility of the establishment of organoids for drug response assays and thus, for the personalized treatment of colorectal carcinomatosis patients., The work in the authors’ laboratory is funded by Instituto de Salud Carlos III (ISCIII) (ICI20/00057 CIBERONC/CB16/12/00273, CIBERONC/CB16/12/00398) and co-funded by the European Union-Fondo Europeo de Desarrollo Regional (FEDER), and the Agencia Estatal de Investigación (PID2019-104867RB-I00/AEI/10.13039/501100011033). DV is supported by a Sociedad Española de Oncología Médica (SEOM)-Río Hortega contract., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Wnt and vitamin D at the crossroads in solid cancer

  • González-Sancho, José Manuel
  • Larriba, María Jesús
  • Muñoz Terol, Alberto
Abnormal activation of the Wnt/β-catenin pathway is common in many types of solidcancers. Likewise, a large proportion of cancer patients have vitamin D deficiency. In line with these observations, Wnt/β-catenin signaling and 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active vitamin D metabolite, usually have opposite effects on cancer cell proliferation and phenotype. In recent years, an increasing number of studies performed in a variety of cancer types have revealed a complex crosstalk between Wnt/β-catenin signaling and 1,25(OH)2D3. Here we review the mechanisms by which 1,25(OH)2D3 inhibits Wnt/β-catenin signaling and, conversely, how the activated Wnt/β-catenin pathway may abrogate vitamin D action. The available data suggest that interaction between Wnt/β-catenin signaling and the vitamin D system is at the crossroads in solid cancers and may have therapeutic applications., The work in the authors’ laboratory is funded by the Agencia Estatal de Investigación (PID2019-104867RB-I00/AEI/10.13039/501100011033), the Agencia Estatal de Investigación—Fondo Europeo de Desarrollo Regional (SAF2016-76377-R, MINECO/AEI/FEDER, EU), the Ministerio de Economía y Competitividad (SAF2017-90604-REDT/NuRCaMeIn), and the Instituto de Salud Carlos III—Fondo Europeo de Desarrollo Regional (CIBERONC; CB16/12/00273)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

From molecular basis to clinical insights: a challenging future for the vitamin D endocrine system in colorectal cancer

  • Pereira, Fábio
  • Fernández-Barral, Asunción
  • Larriba, María Jesús
  • Barbáchano, Antonio
  • González-Sancho, José Manuel
Colorectal cancer (CRC) is one of the most life-threatening neoplasias in terms of incidence and mortality worldwide. Vitamin D deficiency has been associated with an increased risk of CRC. 1α,25-Dihydroxyvitamin D3 [1,25(OH)2D3], the most active vitamin D metabolite, is a pleiotropic hormone that, through its binding to a transcription factor of the nuclear receptor superfamily, is a major regulator of the human genome. 1,25(OH)2D3 acts on colon carcinoma and stromal cells and displays tumor protective actions. Here, we review the variety of molecular mechanisms underlying the effects of 1,25(OH)2D3 in CRC, which affect multiple processes that are dysregulated during tumor initiation and progression. Additionally, we discuss the epidemiological data that associate vitamin D deficiency and CRC, and the most relevant randomized controlled trials of vitamin D3 supplementation conducted in both healthy individuals and CRC patients., The work in the authors' laboratory is funded by the Agencia Estatal de Investigación (PID2019-104867RB-I00 and PID2022-136729OB-I00; MCIN/AEI/10.13039/501100011033), the Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional (CIBERONC/CB16/12/00273 and ICI20/00057), and the Comunidad de Madrid (S2022/BMD-7212). AF-B, MJL, AB, and JMG-S belong to the Spanish National Research Council (CSIC)'s Cancer Hub., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Vitamin D Receptor Deficiency Upregulates Pulmonary Artery Kv7 Channel Activity

  • Olivencia, Miguel A.
  • Villegas-Esguevillas, Marta
  • López Sancho, José María
  • Barreira, Bianca
  • Paternoster, Elena
  • Adão, Rui
  • Larriba, María Jesús
  • Cogolludo, Angel
  • Pérez-Vizcaíno, Francisco
Recent evidence suggests that vitamin D is involved in the development of pulmonary arterial hypertension (PAH). The aim of this study was to analyze the electrophysiological and contractile properties of pulmonary arteries (PAs) in vitamin D receptor knockout mice (Vdr−/−). PAs were dissected and mounted in a wire myograph. Potassium membrane currents were recorded in freshly isolated PA smooth muscle cells (PASMCs) using the conventional whole-cell configuration of the patch-clamp technique. Potential vitamin D response elements (VDREs) in Kv7 channels coding genes were studied, and their protein expression was analyzed. Vdr−/− mice did not show a pulmonary hypertensive phenotype, as neither right ventricular hypertrophy nor endothelial dysfunction was apparent. However, resistance PA from these mice exhibited increased response to retigabine, a Kv7 activator, compared to controls and heterozygous mice. Furthermore, the current sensitive to XE991, a Kv7 inhibitor, was also higher in PASMCs from knockout mice. A possible VDRE was found in the gene coding for KCNE4, the regulatory subunit of Kv7.4. Accordingly, Vdr−/− mice showed an increased expression of KCNE4 in the lungs, with no changes in Kv7.1 and Kv7.4. These results indicate that the absence of Vdr in mice, as occurred with vitamin D deficient rats, is not sufficient to induce PAH. However, the contribution of Kv7 channel currents to the regulation of PA tone is increased in Vdr−/− mice, resembling animals and humans suffering from PAH., The work in the authors’ laboratories is funded by the Agencia Estatal de Investigación (PID2019-104867RB-I00 and PID2020-117939RB-I00, PID/AEI/10.13039/501100011033), the Instituto de Salud Carlos III—Fondo Europeo de Desarrollo Regional (CIBERES/CB06/06/1084 and CIBERONC/CB16/12/00273), and the Fundación contra la hipertensión pulmonar (FCHP). M.J.L. belongs to the Spanish National Research Council (CSIC)’s Cancer Hub. M.A.O. is funded by Universidad Complutense/Banco Santander CT63/19-CT64/19. R.A. has received funding from the European Union’s Horizon 2020 research and innovation programme under Marie-Curie grant agreement Nº 847635., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer

  • Montero, Juan Carlos
  • Carmen, Sofía del
  • Abad, Mar
  • Sayagués, José María
  • Barbáchano, Antonio
  • Fernández-Barral, Asunción
  • Muñoz Terol, Alberto
  • Pandiella, Atanasio
[Background]: Advanced colorectal cancer (CRC) is difficult to treat. For that reason, the development of novel therapeutics is necessary. Here we describe a potentially actionable plasma membrane target, the amino acid transporter protein subunit CD98hc. [Methods]: Western blot and immunohistochemical analyses of CD98hc protein expression were carried out on paired normal and tumoral tissues from patients with CRC. Immunofluorescence and western studies were used to characterize the action of a DM1-based CD98hc-directed antibody–drug conjugate (ADC). MTT and Annexin V studies were performed to evaluate the effect of the anti-CD98hc-ADC on cell proliferation and apoptosis. CRISPR/Cas9 and shRNA were used to explore the specificity of the ADC. In vitro analyses of the antitumoral activity of the anti-CD98hc-ADC on 3D patient-derived normal as well as tumoral organoids were also carried out. Xenografted CRC cells and a PDX were used to analyze the antitumoral properties of the anti-CD98hc-ADC. [Results]: Genomic as well proteomic analyses of paired normal and tumoral samples showed that CD98hc expression was significantly higher in tumoral tissues as compared to levels of CD98hc present in the normal colonic tissue. In human CRC cell lines, an ADC that recognized the CD98hc ectodomain, reached the lysosomes and exerted potent antitumoral activity. The specificity of the CD98hc-directed ADC was demonstrated using CRC cells in which CD98hc was decreased by shRNA or deleted using CRISPR/Cas9. Studies in patient-derived organoids verified the antitumoral action of the anti-CD98hc-ADC, which largely spared normal tissue-derived colon organoids. In vivo studies using xenografted CRC cells or patient-derived xenografts confirmed the antitumoral activity of the anti-CD98hc-ADC. [Conclusions]: The studies herewith reported indicate that CD98hc may represent a novel ADC target that, upon well-designed clinical trials, could be used to increase the therapeutic armamentarium against CRC., JCM: Instituto de Salud Carlos III through a Miguel Servet program (CPII17/00015) and (PI18/00796). AP: Ministry of Economy and Competitiveness of Spain (PID2020-115605RB-I00), the Instituto de Salud Carlos III through CIBERONC, Junta de Castilla y León (CSI146P20), ALMOM, ACMUMA, UCCTA, and the CRIS Cancer Foundation. AM, AB and AF-B: Instituto de Salud Carlos III (ICI20/00057, CIBERONC/CB16/12/00273) and Agencia Estatal de Investigación (PID2019-104867RB-I00/AEI/10.13039/501100011033). The work described here was co-funded by the European Community through the European Regional Development Fund/European Social Fund "A way to make Europe"/"Investing in your future"., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Vitamin D induces SIRT1 activation through K610 deacetylation in colon cancer

  • García-Martínez, José Manuel
  • Chocarro-Calvo, Ana
  • Martínez-Useros, Javier
  • Fernandez-Aceñero, M. Jesús
  • Fiuza, M. Carmen
  • Cáceres-Rentero, José
  • Vieja, Antonio de la
  • Barbáchano, Antonio
  • Muñoz Terol, Alberto
  • Larriba, María Jesús
  • García-Jiménez, Custodia
Posttranslational modifications of epigenetic modifiers provide a flexible and timely mechanism for rapid adaptations to the dynamic environment of cancer cells. SIRT1 is an NAD+ -dependent epigenetic modifier whose activity is classically associated with healthy aging and longevity, but its function in cancer is not well understood. Here, we reveal that 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3 , calcitriol), the active metabolite of vitamin D (VD), promotes SIRT1 activation through auto-deacetylation in human colon carcinoma cells, and identify lysine 610 as an essential driver of SIRT1 activity. Remarkably, our data show that the post-translational control of SIRT1 activity mediates the antiproliferative action of 1,25(OH)2D3 . This effect is reproduced by the SIRT1 activator SRT1720, suggesting that SIRT1 activators may offer new therapeutic possibilities for colon cancer patients who are VD deficient or unresponsive. Moreover, this might be extrapolated to inflammation and other VD deficiency-associated and highly prevalent diseases in which SIRT1 plays a prominent role., Funding for this work was provided by the Agencia Estatal de Investigación (PID2019- 104867RB-I00 / AEI/10.13039/501100011033, RTI2018-099343-B-100 and PID2021-127645OAI00); Instituto de Salud Carlos III (CIBERONC, CB16/12/00273 and CB16/12/00326); Comunidad de Madrid (Ayudas Atracción de Talento 2017-T1/BMD-5334 and 2021-5A/BMD-20951; A385- DROPLET Young Reserchers R&D Project 2019 CAM-URJC; PRECICOLON-CM, P2022/BMD7212); Universidad Rey Juan Carlos (ADIPOMELM, Proyecto Puente de Investigación 2020)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

PKD phosphorylation and COP9/Signalosome modulate intracellular Spry2 protein stability

  • Martínez, Natalia
  • Gragera, Teresa
  • Lucas, María Pilar de
  • Cámara, Ana Belén
  • Ballester, Alicia
  • Anta, Berta
  • Fernández-Medarde, Alberto
  • López-Briones, T.
  • Ortega, Judith
  • Peña Jiménez, Daniel
  • Barbáchano, Antonio
  • Montero-Calle, Ana
  • Cordero, Víctor
  • Barderas, Rodrigo
  • Iglesias, Teresa
  • Yunta, M.
  • Oliva, José Luis
  • Muñoz, Alberto
  • Santos de Dios, Eugenio
  • Zarich, Natasha
  • Rojas-Cabañeros, José M.
Spry2 is a molecular modulator of tyrosine kinase receptor signaling pathways that has cancer-type-specific effects. Mammalian Spry2 protein undergoes tyrosine and serine phosphorylation in response to growth factor stimulation. Spry2 expression is distinctly altered in various cancer types. Inhibition of the proteasome functionality results in reduced intracellular Spry2 degradation. Using in vitro and in vivo assays, we show that protein kinase D (PKD) phosphorylates Spry2 at serine 112 and interacts in vivo with the C-terminal half of this protein. Importantly, missense mutation of Ser112 decreases the rate of Spry2 intracellular protein degradation. Either knocking down the expression of all three mammalian PKD isoforms or blocking their kinase activity with a specific inhibitor contributes to the stabilization of Spry2 wild-type protein. Downregulation of CSN3, a component of the COP9/Signalosome that binds PKD, significantly increases the half-life of Spry2 wild-type protein but does not affect the stability of a Spry2 after mutating Ser112 to the non-phosphorylatable residue alanine. Our data demonstrate that both PKD and the COP9/Signalosome play a significant role in control of Spry2 intracellular stability and support the consideration of the PKD/COP9 complex as a potential therapeutic target in tumors where Spry2 expression is reduced., JMR-C received grant support from MINECO-FEDER (SAF2016-78852-R), AESI-ISCIII (PI20CIII/00029) and Spanish Association against Cancer (AECC, CGB14143035THOM). ES group was supported by grants from ISCIII-MCUI (FIS PI19/00934), JCyL (SA264P18-UIC 076), Areces Foundation (CIVP19A5942), Solorzano-Barruso Foundation (FS/32–2020) and by ISCIII-CIBERONC (group CB16/12/00352). Funding to AM group was provided by the Agencia Estatal de Investigación (PID2019-104867RB-I00/AEI/10.13039/501100011033) and by ISCIII-CIBERONC (group CB16/12/00273). TI was supported by grant PID2020-115218RB-I00 funded by MCIN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe” and by ISCIII-CIBERNED. RB received grant support from AESI-ISCIII (PI20CIII/00019). Finally, DP-J and MY groups were supported by grants 1.012.022 (to DP-J), 1.010.929 and 1.400.002 (both to MY) from Fundación Universidad Alfonso X el Sabio (FUAX). All research co-financed by FEDER funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

ERK2 stimulates MYC transcription by anchoring CDK9 to the MYC promoter in a kinase activity-independent manner

  • Agudo-Ibáñez, Lorena
  • Morante, Marta
  • García-Gutiérrez, Lucía
  • Quintanilla, Andrea
  • Rodríguez, Javier M.
  • Muñoz Terol, Alberto
  • León, Javier
  • Crespo, Piero
The transcription factor MYC regulates cell proliferation, transformation, and survival in response to growth factor signaling that is mediated in part by the kinase activity of ERK2. Because ERK2 can also bind to DNA to modify gene expression, we investigated whether it more directly regulates MYC transcription. We identified ERK2 binding sites in the MYC promoter and detected ERK2 at the promoter in various serum-stimulated cell types. Expression of nuclear-localized ERK2 constructs in serum-starved cells revealed that ERK2 in the nucleus—regardless of its kinase activity—increased MYC mRNA expression and MYC protein abundance. ERK2 bound to the promoter through its amino-terminal insert domain and to the cyclin-dependent kinase CDK9 (which activates RNA polymerase II) through its carboxyl-terminal conserved docking domain. Both interactions were essential for ERK2-induced MYC expression, and depleting ERK impaired CDK9 occupancy and RNA polymerase II progression at the MYC promoter. Artificially tethering CDK9 to the MYC promoter by fusing it to the ERK2 insert domain was sufficient to stimulate MYC expression in serum-starved cells. Our findings demonstrate a role for ERK2 at the MYC promoter acting as a kinase-independent anchor for the recruitment of CDK9 to promote MYC expression., The work was supported by grants RTI2018-096658B-100 to P.C., PID2020-115903GB-100 to J.L., and PID2019-104867RB-100 to A.M. from the Spanish Ministry of Science (MCIN/AEI/10.13039/501100011033/, Spanish Government and FEDER); a grant from Asociación Española Contra el Cancer (AECC; GCB141423113) to P.C.; and a grant from CIBERONC from (CB16/12/00273) from Instituto de Salud Carlos III-FEDER to P.C. and A.M.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Vitamin D opposes multilineage cell differentiation induced by Notch inhibition and BMP4 pathway activation in human colon organoids

  • Bustamante-Madrid, Pilar
  • Barbáchano, Antonio
  • Albandea-Rodríguez, David
  • Rodríguez-Cobos, Javier
  • Rodríguez-Salas, Nuria
  • Prieto, Isabel
  • Burgos, Aurora
  • Martínez de Villarreal, Jaime
  • Real, Francisco X.
  • González-Sancho, José Manuel
  • Larriba, María Jesús
  • Lafarga, Miguel
  • Muñoz Terol, Alberto
  • Fernández-Barral, Asunción
Understanding the mechanisms involved in colonic epithelial differentiation is key to unraveling the alterations causing inflammatory conditions and cancer. Organoid cultures provide an unique tool to address these questions but studies are scarce. We report a differentiation system toward enterocytes and goblet cells, the two major colonic epithelial cell lineages, using colon organoids generated from healthy tissue of colorectal cancer patients. Culture of these organoids in medium lacking stemness agents resulted in a modest ultrastructural differentiation phenotype with low-level expression of enterocyte (KLF4, KRT20, CA1, FABP2) and goblet cell (TFF2, TFF3, AGR2) lineage markers. BMP pathway activation through depletion of Noggin and addition of BMP4 resulted in enterocyte-biased differentiation. Contrarily, blockade of the Notch pathway using the γ-secretase inhibitor dibenzazepine (DBZ) favored goblet cell differentiation. Combination treatment with BMP4 and DBZ caused a balanced strong induction of both lineages. In contrast, colon tumor organoids responded poorly to BMP4 showing only weak signals of cell differentiation, and were unresponsive to DBZ. We also investigated the effects of 1α,25-dihydroxyvitamin D3 (calcitriol) on differentiation. Calcitriol attenuated the effects of BMP4 and DBZ on colon normal organoids, with reduced expression of differentiation genes and phenotype. Consistently, in normal organoids, calcitriol inhibited early signaling by BMP4 as assessed by reduction of the level of phospho-SMAD1/5/8. Our results show that BMP and Notch signaling play key roles in human colon stem cell differentiation to the enterocytic and goblet cell lineages and that calcitriol modulates these processes favoring stemness features., This work was supported by grant PID2019-104867RB-I00 funded by MCIN/AEI/10.13039/501100011033; grant PID2022-136729OB-I00 funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe”; grant S2022/BMD-7212 funded by Comunidad de Madrid; and grants ICI20/00057, CIBERONC/CB16/12/00273, CIBERONC/CB16/12/00453 and CIBERONC/CB16/12/00398 funded by the Instituto de Salud Carlos III - Fondo Europeo de Desarrollo Regional. PB-M and DA-R were supported by grants BES-2017-082483 and PRE2020-092713, respectively, funded by MCIN/AEI/10.13039/501100011033 and “ESF Investing in your future”. PB-M, AB, DA-R, JR-C, JMG-S, MJL, AM and AF-B belong to the Spanish National Research Council (CSIC)‘s Cancer Hub., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SIRT1 Mediates the Antagonism of Wnt/β-Catenin Pathway by Vitamin D in Colon Carcinoma Cells

  • García-Martínez, José Manuel
  • Chocarro-Calvo, Ana
  • Martínez-Useros, Javier
  • Regueira-Acebedo, Nerea
  • Fernandez-Aceñero, M. Jesús
  • Muñoz, Alberto
  • Larriba, María Jesús
  • García-Jiménez, Custodia
Cancer initiation and progression result from genetic and epigenetic alterations caused by interactions between environmental and endogenous factors leading to aberrant cell signalling. Colorectal cancers (CRC) are linked to abnormal activation of the Wnt/β-catenin pathway, whose key feature is the nuclear accumulation of acetylated β-catenin in colon epithelial cells. Nuclear β-catenin acts as a transcriptional co-activator, targeting genes involved in cell proliferation and invasion. 1α,25-Dihydroxyvitamin D3 (1,25(OH)2D3 or calcitriol), the active form of vitamin D, antagonizes Wnt/β-catenin over-activation by engaging its high affinity receptor, VDR. Here we unveil that 1,25(OH)2D3-bound VDR activates Silent Information Regulator of Transcription, sirtuin 1 (SIRT1), leading to β-catenin deacetylation and nuclear exclusion, downregulation of its pro-tumourigenic target genes and inhibition of human colon carcinoma cell proliferation. Notably, orthogonal SIRT1 activation mimics nuclear exclusion of β-catenin while SIRT1 inhibition blocks the effects of 1,25(OH)2D3. Thus, SIRT1 emerges as a crucial mediator in the protective action of vitamin D against CRC. The mutual negative feedback loop unveiled here between Wnt and SIRT1 represents an important surrogate target in CRC. Since nuclear localisation of β-catenin is a critical driver of CRC that requires its acetylation, we provide a mechanistic foundation for the epidemiological evidence linking vitamin D deficiency and increased CRC risk and mortality., Funding for this work was provided by the Agencia Estatal de Investigación MCIN/AEI/10.13039/501100011033 (PID2019-104867RB-I00); Agencia Estatal de Investigación MCIN/AEI/10.13039/501100011033 and FEDER Una manera de hacer Europa (PID2021-127645OA-I00 and PID2022-136729OB-I00); Comunidad de Madrid (PEJ-2021-AI/BMD-22973 and PEJ-2021-TL/BMD-21515; Ayudas Atracción de Talento 2017-T1/BMD-5334 and 2021-5A/BMD-20951; A385-DROPLET Young Researchers R&D Project 2019 CAM-URJC; PRECICOLON-CM, P2022/BMD-7212); Universidad Rey Juan Carlos (ADIPOMELM, Proyecto Puente de Investigación 2020); and Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional (CIBER-ONC/CB16/12/00273)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Gasdermin-B (GSDMB) takes center stage in antibacterial defense, inflammatory diseases, and cancer

  • Sarrió, David
  • Colomo, Sara
  • Moreno-Bueno, Gema
One of the hottest topics in biomedical research is to decipher the functional implications of the Gasdermin (GSDM) protein family in human pathologies. These proteins are the key effectors of a lytic and pro-inflammatory cell death type termed pyroptosis (also known as “Gasdermin-mediated programmed cell death”). However, ever-growing evidence showed that GSDMs can play multiple and complex roles in a context-dependent manner. In this sense, Gasdermin-B (GSDMB; the only GSDM gene absent in mice and rats) has been implicated in antibacterial defense, numerous inflammatory pathologies (e.g., asthma, ulcerative colitis), and cancer, but both cell death-dependent and -independent functions have been reported in these diseases, fueling the debate on whether GSDMB has genuine pyroptotic capacity. Recently, a series of seminal papers cast light on the GSDMB multitasking capacity by showing that different GSDMB transcriptional isoforms have distinct biological activities. Nonetheless, there are still obscure areas to be clarified on the precise functional involvement of GSDMB translated variants in physiological and pathological conditions. In this viewpoint, we critically discuss the most recent and exciting data on this topic and propose a series of relevant challenges that need to be overcome before GSDMB-driven biomedical applications (as a biomarker of disease risk/progression/outcome or as specific therapeutic target) become a reality in clinical settings., This study was financed by the following grants: Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (MICINN-AEI, PID2019-104644RB-I00, PDC2022-133252-I00, PID2022-136854OB-I00), the Instituto de Salud Carlos III (CIBERONC, CB16/12/00295), AC21_2/00020 ERA PerMed ERA-NET (cofunded by NextGenerationEU) and the AECC Scientific Foundation (FCAECC PROYE19036MOR and GCTRA18014MATI). DS contract is financed by CIBERONC (partly supported by FEDER funds). SC is funded by the MICINN-AEI PRE2020-095658., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeted radioiodine therapy of ovarian cancer via the sodium/iodide symporter (NIS)

  • Mirela Mielu, Lidia
  • Rodal-Bravo, Lucía
  • Diego-Hernández, Cristina
  • Varona, Sarai
  • Fajardo-Delgado, Dánae
  • Hortiguela, Rafael
  • Torres-Ruiz, Mónica
  • Cuesta, Isabel
  • Pallares, Pilar
  • Santisteban, Pilar
  • García-Jiménez, Custodia
  • Martín-Duque, Pilar
  • Vieja, Antonio de la
[Objective] Ovarian cancer is the most lethal gynecological malignancy, but current treatments have not improved overall survival and recurrence rates. New therapies are needed and, in this context, we propose the use of the sodium/iodide symporter (NIS) that enables effective targeted Radioiodide therapy (RAI), as NIS is overexpressed in ovarian cancer., [Methods] Using datasets and patient samples of human ovarian tumors, we determine the expression of NIS and canonical epithelial markers. We characterized NIS expression and function in human derived cell lines and tested the in vivo functional expression of NIS using Single Photon Emission Computed Tomography (SPECT). We also compared the efficacy of RAI versus chemotherapeutic treatments (cisplatin and paclitaxel) in mouse models., [Results] Human ovarian tumors expressed NIS, predominantly in a non-glycosylated form, with plasma membrane localization. Datasets and RNAseq confirmed NIS expression in ovarian epithelial tumors. Functional NIS expression was observed both in vitro and in vivo. In preclinical ovarian cancer mouse models, RAI therapy with 131I greatly reduced or eliminated tumors, was more effective, and had fewer secondary effects than classical treatments (cisplatin and paclitaxel), although both could be combined., [Conclusions] Our findings highlight that RAI through NIS could serve as a therapeutic agent in ovarian cancer. Additionally, it may enable non-invasive imaging and monitoring of disease progression., This work was supported by grants from the Spanish Ministerio de Ciencia e Innovacion (MICIN) and Fondo Europeo de Desarrollo Regional (FEDER) RTI2018–099343-B-100 and PID2023-151128OB-I00/AEI/10.13039/501100011033 to ADlV., PID2019–105303RBI00/AEI/10.13039/501100011033 to P.S., and PID2019–104867RB-I00/AEI/10.13039/501100011033 and PRECICOLON-CM P2022/BMD7212 to C.G-J., as well as CIBERONC CB16/12/00326 from Instituto de Salud Carlos III (ISCIII) to ADlV and P.S. Predoctoral fellowship from CIBERONC to L.M.M. Instituto de Salud Carlos III (ISCIII) (AESI 2024 PI24CIII/00046) and AECC grants Aragon/FEDER 2014–2020 “Building Europe from Aragon”, Spain to PM-D. This work was performed as partial fulfillment of the doctoral thesis of LMM at the Universidad Autonoma de Madrid (UAM) in Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Calcitriol modulates age-dependent drug response in paired patient-derived normal and tumor colorectal organoids

  • Fernández-Barral, Asunción
  • Barbáchano, Antonio
  • Rodríguez-Marrero, Silvia
  • Peso, Luis del
  • Herreros-Cabello, Alfonso
  • Arroyo-Gascón, Estrella
  • Rodríguez-Salas, Nuria
  • Prieto, Isabel
  • Burgos, Aurora
  • León-Arellano, Miguel
  • García-Olmo, Damián
  • Olleros, Tomás
  • González-Sancho, José Manuel
  • Larriba, María Jesús
  • Muñoz, Alberto
The incidence of early-onset colorectal cancer (EO-CRC, <50 years) is rising worldwide, highlighting the need to better understand the underlying causes of this age-related divergence. We used paired patient-derived normal and tumor colorectal organoids to investigate the therapeutic window of chemotherapeutic agents and its modulation by calcitriol (the most active vitamin D metabolite). Dose-response analyses revealed marked interpatient variability, with SN38 being more potent than 5-fluorouracil (5-FU) and oxaliplatin. Normal organoids were more resistant than paired tumor counterparts to 5-FU and oxaliplatin in both EO-CRC and late-onset CRC (LO-CRC, >50 years), indicating selective tumor cytotoxicity. In contrast, the therapeutic window for SN38 was preserved in LO-CRC but not in EO-CRC organoids, revealing age-dependent differences in drug sensitivity. Moreover, calcitriol reduced the cytotoxicity of 5-FU and SN38 in normal organoids regardless of patient age, while in tumor organoids this protective effect was restricted to EO-CRC. As a consequence, calcitriol treatment selectively expanded the therapeutic window for 5-FU and SN38 in LO-CRC organoids. Mechanistically, these effects correlated with calcitriol-induced antiproliferative action and transcriptional regulation of drug metabolism-related pathways. Overall, our findings identify age-dependent differences in chemotherapy response and support the importance of maintaining adequate vitamin D status to reduce chemotherapy-associated toxicity., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project ICI20/00057 and co-funded by the European Union. Additional support was provided by grants CIBERONC/CB16/12/00273, CIBERONC/CB16/12/00398, and CIBERES/CB15/00037 funded by the Instituto de Salud Carlos III (ISCIII) - FEDER, UE. This work was also supported by grant PID2019-104867RB-I00 funded by MICIU/AEI/10.13039/501100011033; grant PID2022-136729OB-I00 funded by MICIU/AEI/10.13039/501100011033 and FEDER, UE and grant S2022/BMD-7212 funded by Comunidad de Madrid. SR-M was supported by grant PREP2022-000611 funded by MICIU/AEI/10.13039/501100011033 and FSE+. EA-G was supported by grant FPU24/03135 funded by Ministerio de Ciencia, Innovación y Universidades. AF-B, AB, SR-M, AH-C, EA-G, JMG-S, MJL and AM belong to the Spanish National Research Council (CSIC)'s Cancer Hub., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Vitamin D opposes multilineage cell differentiation induced by Notch inhibition and BMP4 pathway activation in human colon organoids

  • Bustamante Madrid, Pilar
  • Barbáchano, Antonio
  • Albandea Rodríguez, David
  • Rodríguez Cobos, Javier
  • Rodríguez Salas, Nuria
  • Prieto Nieto, Isabel
  • Burgos García, Aurora
  • Martínez de Villarreal, Jaime
  • Real, Francisco X.
  • González Sancho, José Manuel
  • Larriba, María Jesús
  • Lafarga, Miguel
  • Muñoz, Alberto
  • Fernández Barral, Asunción
Understanding the mechanisms involved in colonic epithelial differentiation is key to unraveling the alterations causing inflammatory conditions and cancer. Organoid cultures provide an unique tool to address these questions but studies are scarce. We report a differentiation system toward enterocytes and goblet cells, the two major colonic epithelial cell lineages, using colon organoids generated from healthy tissue of colorectal cancer patients. Culture of these organoids in medium lacking stemness agents resulted in a modest ultrastructural differentiation phenotype with low-level expression of enterocyte (KLF4, KRT20, CA1, FABP2) and goblet cell (TFF2, TFF3, AGR2) lineage markers. BMP pathway activation through depletion of Noggin and addition of BMP4 resulted in enterocyte-biased differentiation. Contrarily, blockade of the Notch pathway using the γ-secretase inhibitor dibenzazepine (DBZ) favored goblet cell differentiation. Combination treatment with BMP4 and DBZ caused a balanced strong induction of both lineages. In contrast, colon tumor organoids responded poorly to BMP4 showing only weak signals of cell differentiation, and were unresponsive to DBZ. We also investigated the effects of 1α,25-dihydroxyvitamin D3 (calcitriol) on differentiation. Calcitriol attenuated the effects of BMP4 and DBZ on colon normal organoids, with reduced expression of differentiation genes and phenotype. Consistently, in normal organoids, calcitriol inhibited early signaling by BMP4 as assessed by reduction of the level of phospho-SMAD1/5/8. Our results show that BMP and Notch signaling play key roles in human colon stem cell differentiation to the enterocytic and goblet cell lineages and that calcitriol modulates these processes favoring stemness features., This work was supported by grant PID2019-104867RB-I00 funded by MCIN/AEI/10.13039/501100011033; grant PID2022-136729OB-I00 funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe”; grant S2022/BMD-7212 funded by Comunidad de Madrid; and grants ICI20/00057, CIBERONC/CB16/12/00273, CIBERONC/CB16/12/00453 and CIBERONC/CB16/12/00398 funded by the Instituto de Salud Carlos III - Fondo Europeo de Desarrollo Regional. PB-M and DA-R were supported by grants BES-2017-082483 and PRE2020-092713, respectively, funded by MCIN/AEI/10.13039/501100011033 and “ESF Investing in your future”. PB-M, AB, DA-R, JR-C, JMG-S, MJL, AM and AF-B belong to the Spanish National Research Council (CSIC)‘s Cancer Hub.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis

  • Solé Font, Laura|||0000-0002-3195-0565
  • Lobo-Jarne, Teresa|||0000-0002-1632-438X
  • Álvarez-Villanueva, Daniel
  • Alonso-Marañón, Josune
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Guix, Marta|||0000-0002-2143-0697
  • Sangrador, Irene
  • Rozalén, Catalina
  • Vert, Anna
  • Barbachano, Antonio|||0000-0002-1248-5143
  • Lop Gros, Joan|||0000-0002-9442-5688
  • Salido, Marta|||0000-0001-9988-5977
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • García-Romero, Raquel
  • Garrido, Marta
  • González Miranda, Jessica|||0000-0001-7732-1564
  • Martínez-Iniesta, María
  • López-Arribillaga, Erika|||0000-0002-9451-6635
  • Salazar, Ramón
  • Torres, Ferran|||0000-0002-7355-7913
  • Iglesias, Mar|||0000-0002-2274-4671
  • Celià-Terrassa, Toni|||0000-0002-0615-8744
  • Muñoz, Alberto|||0000-0003-3890-4251
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. Using CRC patient-derived organoids (PDO)s, we show that sublethal doses of chemotherapy (CT) does not select previously resistant tumor populations but induces a quiescent state specifically to TP53 wildtype (WT) cancer cells, which is linked to the acquisition of a YAP1-dependent fetal phenotype. Cells displaying this phenotype exhibit high tumor-initiating and metastatic activity. Nuclear YAP1 and fetal traits are present in a proportion of tumors at diagnosis and predict poor prognosis in patients carrying TP53 WT CRC tumors. We provide data indicating the higher efficacy of CT together with YAP1 inhibitors for eradication of therapy resistant TP53 WT cancer cells. Together these results identify fetal conversion as a useful biomarker for patient prognosis and therapy prescription.